Listen to our latest Investing Matters Podcast episode 'Uncovering opportunities with investment trusts' with The AIC's Richard Stone here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCroda International Regulatory News (CRDA)

Share Price Information for Croda International (CRDA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4,065.00
Bid: 4,060.00
Ask: 4,061.00
Change: 38.00 (0.94%)
Spread: 1.00 (0.025%)
Open: 4,049.00
High: 4,077.00
Low: 4,022.00
Prev. Close: 4,027.00
CRDA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

First quarter trading statement

26 Apr 2012 07:00

RNS Number : 0818C
Croda International PLC
26 April 2012
 



26 April 2012

 

Croda International Plc

 

First quarter trading statement

 

STRONG START TO 2012

 

 

Martin Flower, Chairman of Croda International Plc, is due to provide the following update on first quarter trading for the period ended 31 March 2012 at today's Annual General Meeting:

 

"I am pleased to report that we achieved record Group results in the first three months of 2012, driven by our highest ever quarterly sales and profits in both Consumer Care and Performance Technologies.

 

Group sales from continuing operations increased 4.7% to £291.0m (2011: £277.9m). We achieved sales growth in all the major geographical areas in which we operate and volumes were much improved versus the run rates seen during the second half of 2011. Group operating profit from continuing operations was up 8.0% to £65.8m (2011: £60.9m).

 

Group pre-tax profit from continuing operations increased 7.2% to £65.1m (2011: £60.7m).

 

All business areas within Consumer Care saw very good growth, resulting in a sales uplift of 9.2% to £159.7m (2011: £146.3m) and a 13.7% increase in operating profit to £48.2m (2011: £42.4m). Return on sales was 30.2%.

 

Performance Technologies sales increased by 2.9% to £106.9m (2011: £103.9m), in line with expectations, and operating profit increased by 1.2% to £16.3m (2011: £16.1m). Return on sales was 15.2%. This was an encouraging result against very strong comparatives in the first quarter of 2011 when we experienced profit growth of 56.3%.

 

In Industrial Chemicals, which represents less than 2% of Group operating profit, sales fell by 11.9% to £24.4m (2011: £27.7m) due to slow demand in Europe. This led to a 45.8% fall in operating profit to £1.3m (2011: £2.4m).

 

Raw material costs have started to rise and we began to introduce price increases across a number of product areas from April.

 

Strong cash generation and a final receipt of £15.9m from the 2008 sale of our Chicago business reduced net debt by £45.2m to £185.9m (year end 2011: £231.1m).

 

The Board believes that these results represent a strong start to the year and we remain confident that 2012 will be another year of progress for Croda."

 

For further information, please contact:

 

Steve Foots, Group Chief Executive

Tel: 01405 860551

Sean Christie, Group Finance Director

Ben Foster, Pendomer Communications

Tel: 020 3603 5220

 

The company will host a conference call for analysts at 8.00am (BST) today:

Dial-In: 020 3140 0724

Please quote "Croda International"to gain access to the call

 

 

Croda International Plc

Unaudited income statement before tax and exceptional items

 

 

31 March 2012

3 months to

3 months to

31 March

31 March

2012

2011

Change

Consumer Care

159.7

146.3

+9.2%

Performance Technologies

106.9

103.9

+2.9%

Industrial Chemicals

24.4

27.7

-11.9%

Revenues from continuing operations

291.0

277.9

+4.7%

Consumer Care

48.2

42.4

+13.7%

Performance Technologies

16.3

16.1

+1.2%

Industrial Chemicals

1.3

2.4

-45.8%

Operating profit from continuing operations

65.8

60.9

+8.0%

Net bank and loan interest payable

(1.9)

(2.0)

Net retirement benefit scheme financing

1.2

1.8

Profit before tax from continuing operations

65.1

60.7

+7.2%

Operating margin

22.6%

21.9%

 

Analysis of turnover uplift for continuing operations

Volume

-1.5%

Currency impact

-0.2%

Price/mix

+6.4%

+4.7%

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCIAMFTMBMTBLT
Date   Source Headline
12th Sep 20238:56 amRNSDirector/PDMR Shareholding
11th Aug 20232:26 pmRNSDirector/PDMR Shareholding
1st Aug 20237:13 amRNSDirector Declaration
25th Jul 20237:00 amRNSResults for the six months ended 30 June 2023
11th Jul 20232:57 pmRNSDirector/PDMR Shareholding
4th Jul 20238:02 amRNSCroda completes acquisition of Solus Biotech
26th Jun 202310:46 amRNSHolding(s) in Company
13th Jun 20233:55 pmRNSDirector/PDMR Shareholding
12th Jun 20232:06 pmRNSDirector/PDMR Shareholding
9th Jun 20237:00 amRNSTrading update
31st May 20232:47 pmRNSDirector/PDMR Shareholding
26th May 20233:51 pmRNSDirector/PDMR Shareholding
11th May 20234:05 pmRNSDirector/PDMR Shareholding
3rd May 20233:08 pmRNSDirector/PDMR Shareholding
3rd May 20233:00 pmRNSDirector/PDMR Shareholding
2nd May 20232:30 pmRNSDirector/PDMR Shareholding
27th Apr 20239:18 amRNSResult of AGM
24th Apr 20234:49 pmRNSDirector/PDMR Shareholding
12th Apr 20232:00 pmRNSDirector/PDMR Shareholding
28th Mar 20233:51 pmRNSDirector/PDMR Shareholding
28th Mar 20233:50 pmRNSDirector/PDMR Shareholding
28th Mar 20233:47 pmRNSDirector/PDMR Shareholding
28th Mar 20233:46 pmRNSDirector/PDMR Shareholding
28th Mar 20233:44 pmRNSDirector/PDMR Shareholding
28th Mar 20233:42 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
28th Mar 20233:41 pmRNSDirector/PDMR Shareholding
27th Mar 20233:52 pmRNSDirector/PDMR Shareholding
27th Mar 20233:48 pmRNSDirector/PDMR Shareholding
24th Mar 202310:57 amRNSDirector/PDMR Shareholding
24th Mar 202310:31 amRNSDirectorate Change
17th Mar 20235:12 pmRNSAnnual Financial Report
17th Mar 20232:30 pmRNSDirector/PDMR Shareholding
17th Mar 202310:53 amRNSDirector/PDMR Shareholding
13th Mar 20232:02 pmRNSDirector/PDMR Shareholding
3rd Mar 202311:57 amRNSDirector/PDMR Shareholding
28th Feb 20239:21 amRNSDirectorate Change
28th Feb 20237:00 amRNSResults for the year ended 31 December 2022
13th Feb 20232:14 pmRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSAcquisition of Solus Biotech
11th Jan 20233:45 pmRNSDirector/PDMR Shareholding
13th Dec 20223:04 pmRNSDirector/PDMR Shareholding
6th Dec 202212:36 pmRNSDirector/PDMR Shareholding
14th Nov 20223:33 pmRNSHolding(s) in Company
11th Nov 20222:04 pmRNSDirector/PDMR Shareholding
11th Nov 202210:37 amRNSDirector/PDMR Shareholding
11th Nov 202210:33 amRNSDirector/PDMR Shareholding
8th Nov 202211:23 amRNSDirector/PDMR Shareholding
7th Nov 20226:11 pmRNSDirector/PDMR Shareholding
7th Nov 20227:00 amRNSJez Maiden to retire as Group Finance Director

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.